WISH-TV11h
Lilly’s profit doubles in fourth quarter, driven by Mounjaro and Zepbound sales
Lilly's fourth-quarter profit doubles, driven by diabetes and obesity treatments. Strong revenue and forecast for 2025.
The Obesity Market Is Growing Just Fine. But Investors Want to Know What’s Next
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Pros and cons of weight-loss jabs
Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...
Gillingham charity boss hails weight-loss injections including Ozempic, Wegovy and Mounjaro as life-changing after dropping 6st in two months
A charity boss who once tipped the scales at more than 28st says weight-loss injections have changed the way he thinks about ...